GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (NAS:ACHL) » Definitions » Cash Ratio

Achilles Therapeutics (Achilles Therapeutics) Cash Ratio : 7.74 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Achilles Therapeutics's Cash Ratio for the quarter that ended in Dec. 2023 was 7.74.

Achilles Therapeutics has a Cash Ratio of 7.74. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Achilles Therapeutics's Cash Ratio or its related term are showing as below:

ACHL' s Cash Ratio Range Over the Past 10 Years
Min: 7.74   Med: 10.7   Max: 25.3
Current: 7.74

During the past 5 years, Achilles Therapeutics's highest Cash Ratio was 25.30. The lowest was 7.74. And the median was 10.70.

ACHL's Cash Ratio is ranked better than
77.4% of 1522 companies
in the Biotechnology industry
Industry Median: 2.93 vs ACHL: 7.74

Achilles Therapeutics Cash Ratio Historical Data

The historical data trend for Achilles Therapeutics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Cash Ratio Chart

Achilles Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
25.30 10.70 13.94 9.63 7.74

Achilles Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.63 8.83 7.52 7.71 7.74

Competitive Comparison of Achilles Therapeutics's Cash Ratio

For the Biotechnology subindustry, Achilles Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achilles Therapeutics's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achilles Therapeutics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Achilles Therapeutics's Cash Ratio falls into.



Achilles Therapeutics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Achilles Therapeutics's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=131.539/16.996
=7.74

Achilles Therapeutics's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=131.539/16.996
=7.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Achilles Therapeutics  (NAS:ACHL) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Achilles Therapeutics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Achilles Therapeutics (Achilles Therapeutics) Business Description

Traded in Other Exchanges
Address
245 Hammersmith Road, London, GBR, W6 8PW
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics (Achilles Therapeutics) Headlines

From GuruFocus

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

By GuruFocusNews GuruFocusNews 07-01-2022